Krishna Institute of Medical Sciences Releases Q1 Results; Approves Loan Advances and Partnerships
Krishna Institute of Medical Sciences Limited has released its Unaudited Financial Results for the first quarter ended June 30, 2026. The results cover both standalone and consolidated operations. During a Board meeting held on August 3, 2026, the company also approved several corporate actions, including loan advancements and agreements with partner entities.The financial review reports were conducted by S.R. Batliboi & Associates LLP, the statutory auditors.
Financial Performance Overview
Standalone Results (Q1 Ended June 30, 2026)
Krishna Institute of Medical Sciences recorded significant performance metrics in its standalone results for the quarter ended June 30, 2026.| Metric | Quarter Ended 30 Jun 26 (Unaudited) | Q1 FY 26 (Audited/Prior) |
|---|---|---|
| Revenue from operations | 4,836 (Rupees in millions) | 3,734 (Rupees in millions) |
| Other income | 307 (Rupees in millions) | 122 (Rupees in millions) |
| Total Income | 5,143 (Rupees in millions) | 3,856 (Rupees in millions) |
| Profit before tax and exceptional items | 797 (Rupees in millions) | 891 (Rupees in millions) |
| Tax expense (Total) | 209 (Rupees in millions) | 174 (Rupees in millions) |
| Profit for the period | 588 (Rupees in millions) | 657 (Rupees in millions) |
Consolidated Results (Q1 Ended June 30, 2026)
The company's consolidated results reflect the performance of its Group and an associate.| Metric | Quarter Ended 30 Jun 26 (Unaudited) | Q1 FY 25 (Audited/Prior) |
|---|---|---|
| Total Income | 11,959 (Rupees in millions) | 8,787 (Rupees in millions) |
| Profit before tax and exceptional items | 566 (Rupees in millions) | 1,137 (Rupees in millions) |
| Tax expense (Total) | 192 (Rupees in millions) | 287 (Rupees in millions) |
| Profit for the period attributable to owners | 374 (Rupees in millions) | 850 (Rupees in millions) |
Corporate Actions and Governance Decisions
During its board meeting, Krishna Institute of Medical Sciences Limited took several key approvals concerning financing and partnerships.The Board approved the power to advance loans or provide guarantees to any subsidiary, associate, joint venture, or group entity where a director is deemed interested. This lending limit is capped at Rs. 650 Crores (Rupees Six Hundred Fifty Crores) above existing limits under Section 186 of the Companies Act, 2013, pending special resolution approval by shareholders in a forthcoming General Meeting.
Additionally, the company approved a proposal to extend a loan of up to ₹ 25 crore (Rupees Twenty-Five Crores) to KIMS Hospital Enterprises Private Limited, a material subsidiary. The Board also considered and approved the DRAFT Operations and Maintenance Agreement and Call Option Agreement with Golden Lan Solutions Private Limited and Sarwottam Healthcare Private Limited.
The Group operates in one single reportable business segment: "Medical and Healthcare services."
Additional Financial Details
During the current quarter, the company issued 19,867,549 equity shares of face value Rs. 2 each through Qualified Institutions Placement (QIP) at an issue price of Rs. 755 per share, aggregating Rs. 15,000 million. The funds received from QIP (net of issue expenses of Rs. 237 million) have been utilized toward the stated objects in the Placement Document.The Board meeting commenced at 12:15 P.M. and concluded at 4:15 P.M.
KIMS Stock Price Movement
Today, shares of Krishna Institute of Medical Sciences Limited gained strongly, concluding the day's trading at ₹820.6, or 2.65% higher. The stock saw significant activity in post-market sessions, with a total traded volume of 818,769 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: